Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) - Net Assets
Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has net assets worth NT$3.18 Billion TWD (≈ $100.19 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.46 Billion ≈ $140.39 Million USD) and total liabilities (NT$1.28 Billion ≈ $40.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Chunghwa Chemical Synthesis & Biotech Co to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.18 Billion |
| % of Total Assets | 71.37% |
| Annual Growth Rate | 7.98% |
| 5-Year Change | 6.67% |
| 10-Year Change | 74.31% |
| Growth Volatility | 14.47 |
Chunghwa Chemical Synthesis & Biotech Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See Chunghwa Chemical Synthesis & Biotech Co liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2025)
The table below shows the annual net assets of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2025. For live valuation and market cap data, see how much is Chunghwa Chemical Synthesis & Biotech Co worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.09 Billion ≈ $97.27 Million |
-8.03% |
| 2024-12-31 | NT$3.36 Billion ≈ $105.76 Million |
+0.20% |
| 2023-12-31 | NT$3.35 Billion ≈ $105.55 Million |
+4.92% |
| 2022-12-31 | NT$3.19 Billion ≈ $100.60 Million |
+10.32% |
| 2021-12-31 | NT$2.89 Billion ≈ $91.19 Million |
+15.83% |
| 2020-12-31 | NT$2.50 Billion ≈ $78.72 Million |
+24.00% |
| 2019-12-31 | NT$2.02 Billion ≈ $63.49 Million |
+1.57% |
| 2018-12-31 | NT$1.98 Billion ≈ $62.50 Million |
+8.93% |
| 2017-12-31 | NT$1.82 Billion ≈ $57.38 Million |
+2.83% |
| 2016-12-31 | NT$1.77 Billion ≈ $55.80 Million |
-4.97% |
| 2015-12-31 | NT$1.86 Billion ≈ $58.72 Million |
+15.34% |
| 2014-12-31 | NT$1.62 Billion ≈ $50.91 Million |
-5.56% |
| 2013-12-31 | NT$1.71 Billion ≈ $53.91 Million |
+2.12% |
| 2012-12-31 | NT$1.68 Billion ≈ $52.79 Million |
-0.06% |
| 2011-12-31 | NT$1.68 Billion ≈ $52.82 Million |
-0.37% |
| 2010-12-31 | NT$1.68 Billion ≈ $53.01 Million |
+40.89% |
| 2009-12-31 | NT$1.19 Billion ≈ $37.63 Million |
+42.60% |
| 2008-12-31 | NT$837.53 Million ≈ $26.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chunghwa Chemical Synthesis & Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12194.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.45 Billion | 46.86% |
| Common Stock | NT$769.18 Million | 24.91% |
| Other Components | NT$871.44 Million | 28.23% |
| Total Equity | NT$3.09 Billion | 100.00% |
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pelthos Therapeutics Inc.
NYSE MKT:PTHS
|
$85.55 Million |
|
Billion Electric Co Ltd
TW:3027
|
$85.56 Million |
|
Rimoni
TA:RIMO
|
$85.57 Million |
|
Dilli Illustrate Inc
KQ:131180
|
$85.63 Million |
|
Pearson PLC
LSE:PSON
|
$85.48 Million |
|
Munsin Garment
TWO:2916
|
$85.41 Million |
|
Téléverbier SA
PA:TVRB
|
$85.40 Million |
|
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.)
NASDAQ:LION
|
$85.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chunghwa Chemical Synthesis & Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,356,940,000 to 3,087,340,000, a change of -269,600,000 (-8.0%).
- Net loss of 243,847,000 reduced equity.
- Dividend payments of 14,736,000 reduced retained earnings.
- Share repurchases of 18,525,000 reduced equity.
- Other comprehensive income decreased equity by 523,283,000.
- Other factors increased equity by 530,791,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-243.85 Million | -7.9% |
| Dividends Paid | NT$14.74 Million | -0.48% |
| Share Repurchases | NT$18.52 Million | -0.6% |
| Other Comprehensive Income | NT$-523.28 Million | -16.95% |
| Other Changes | NT$530.79 Million | +17.19% |
| Total Change | NT$- | -8.03% |
Book Value vs Market Value Analysis
This analysis compares Chunghwa Chemical Synthesis & Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.09x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$16.90 | NT$35.30 | x |
| 2010-12-31 | NT$22.32 | NT$35.30 | x |
| 2011-12-31 | NT$20.52 | NT$35.30 | x |
| 2012-12-31 | NT$21.50 | NT$35.30 | x |
| 2013-12-31 | NT$21.21 | NT$35.30 | x |
| 2014-12-31 | NT$20.20 | NT$35.30 | x |
| 2015-12-31 | NT$23.55 | NT$35.30 | x |
| 2016-12-31 | NT$22.70 | NT$35.30 | x |
| 2017-12-31 | NT$23.28 | NT$35.30 | x |
| 2018-12-31 | NT$25.32 | NT$35.30 | x |
| 2019-12-31 | NT$25.76 | NT$35.30 | x |
| 2020-12-31 | NT$31.90 | NT$35.30 | x |
| 2021-12-31 | NT$36.95 | NT$35.30 | x |
| 2022-12-31 | NT$40.67 | NT$35.30 | x |
| 2023-12-31 | NT$42.90 | NT$35.30 | x |
| 2024-12-31 | NT$44.04 | NT$35.30 | x |
| 2025-12-31 | NT$55.58 | NT$35.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chunghwa Chemical Synthesis & Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.30%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.40x
- Recent ROE (-7.90%) is below the historical average (9.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 15.13% | 14.39% | 0.37x | 2.81x | NT$41.53 Million |
| 2009 | 21.05% | 21.75% | 0.49x | 1.99x | NT$128.66 Million |
| 2010 | 11.69% | 15.62% | 0.51x | 1.48x | NT$27.09 Million |
| 2011 | 10.70% | 14.24% | 0.51x | 1.49x | NT$11.15 Million |
| 2012 | 10.48% | 13.20% | 0.44x | 1.80x | NT$8.01 Million |
| 2013 | 5.86% | 9.28% | 0.34x | 1.84x | NT$-68.29 Million |
| 2014 | 0.93% | 1.54% | 0.30x | 2.04x | NT$-142.52 Million |
| 2015 | 16.80% | 26.53% | 0.40x | 1.56x | NT$124.78 Million |
| 2016 | 3.40% | 5.03% | 0.44x | 1.54x | NT$-116.80 Million |
| 2017 | 4.71% | 7.34% | 0.34x | 1.89x | NT$-96.32 Million |
| 2018 | 11.81% | 22.98% | 0.32x | 1.62x | NT$35.89 Million |
| 2019 | 5.81% | 10.12% | 0.34x | 1.71x | NT$-84.49 Million |
| 2020 | 21.29% | 34.46% | 0.49x | 1.26x | NT$282.03 Million |
| 2021 | 13.85% | 20.72% | 0.44x | 1.51x | NT$111.37 Million |
| 2022 | 14.59% | 22.00% | 0.46x | 1.43x | NT$146.58 Million |
| 2023 | 7.91% | 12.70% | 0.40x | 1.54x | NT$-70.11 Million |
| 2024 | 1.58% | 3.94% | 0.28x | 1.42x | NT$-282.66 Million |
| 2025 | -7.90% | -30.30% | 0.19x | 1.40x | NT$-552.58 Million |
Industry Comparison
This section compares Chunghwa Chemical Synthesis & Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,506,009,667
- Average return on equity (ROE) among peers: 5.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | NT$3.18 Billion | 15.13% | 0.40x | $85.54 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $92.11 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.32 Billion | 9.26% | 0.78x | $190.85 Million |
| Panion & BF Biotech Inc (1760) | $1.93 Billion | 5.40% | 0.53x | $161.80 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $969.06 Million | 16.12% | 0.26x | $101.71 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $31.95 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $44.44 Million |
| Medigen Biotechnology (3176) | $3.46 Billion | -15.61% | 0.30x | $146.59 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $112.36 Million |
| Genovate Biotechnology Co Ltd (4130) | $2.25 Billion | 1.74% | 0.18x | $112.45 Million |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more